Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019
|
By LabMedica International staff writers Posted on 31 Jan 2019 |

Image: The Atellica Solution series of immunoassay and chemistry analyzers (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany) showcased its wide portfolio of products and services in its core areas of laboratory diagnostics and molecular medicine at MedLab Middle East 2019. MedLab is the only medical laboratory industry event that offers manufacturers the opportunity to meet a diverse audience of buyers. From distributors to senior end-users, the 2019 edition welcomed over 19,610 medical lab and trade professionals in search of the latest innovations.
At MedLab Middle East 2019, Siemens highlighted its Atellica Solution series of flexible, scalable, automation-ready immunoassay and chemistry analyzers. The company demonstrated how the Atellica Solution delivers even more control and simplicity for labs with revolutionary sample-management possibilities. The company also promoted its Atellica Solution Assays having of an expanding menu of over 175 assays powered by proven detection technologies. Also on display at the event was Siemens’ Aptio Automation, the total lab automation leader to optimize clinical operations.
Additionally, Siemens highlighted its wide range of assays, including the Atellica IM and ADVIA Centaur high-sensitivity troponin I assay which provide fast, accurate, actionable troponin I results to aid in the diagnosis of acute MI; the Atellica IM and ADVIA Centaur enhanced liver fibrosis test, a minimally invasive blood test with results that correlate to the level of liver fibrosis severity assessed by liver biopsy; the Atellica IM and ADVIA Centaur B·R·A·H·M·S Procalcitonin (PCT) assay which helps achieve earlier sepsis diagnosis and risk assessment to help improve patient outcomes with high low-end sensitivity; and the Atellica IM and ADVIA Centaur vitamin D total assay which helps evaluate the total amount of 25-hydroxy-vitamin D (both D2 and D3) in the blood to provide patients with accurate results, regardless of level and whether or not they are supplemented over-the-counter or by prescription.
Siemens also highlighted its range of point-of-care analyzers, including the epoc blood analysis system which offers complete blood gas and basic metabolic panel with hematocrit and lactate on a single room temperature-stable test card; the Xprecia Stride coagulation analyzer for PT/INR testing that provides high usability and lab-accurate results at the point-of-care; and the Atellica 1500 automated urinalysis system which combines fully automated urine sediment and chemistry analyzers into one streamlined system.
In the field of molecular diagnostics, Siemens demonstrated the Fast Track cycler for molecular testing that uses magnetic induction technology for robust and reliable results, and Syndromic real-time PCR multiplexing assays, one of the largest ranges of syndromically grouped real-time PCR multiplex assays covering the major infectious-disease groups.
Siemens also presented its digital healthcare solutions, including the Atellica Process Manager to operationalize processes with centralized oversight and advanced analytics; Atellica Data Manager to operationalize lab data with open, scalable test-, QC-, and result-management software; the Atellica Inventory Manager to analyze and automate inventory to reduce costs and save time; the POCcelerator Data Management System which is an open POC Informatics solution that can aggregate data from 180+ device models available from more than 40 different vendors; and the FastFinder Software, a fully automated real-time PCR interpretation platform that is compatible with select kits from Fast Track Diagnostics.
At MedLab Middle East 2019, Siemens highlighted its Atellica Solution series of flexible, scalable, automation-ready immunoassay and chemistry analyzers. The company demonstrated how the Atellica Solution delivers even more control and simplicity for labs with revolutionary sample-management possibilities. The company also promoted its Atellica Solution Assays having of an expanding menu of over 175 assays powered by proven detection technologies. Also on display at the event was Siemens’ Aptio Automation, the total lab automation leader to optimize clinical operations.
Additionally, Siemens highlighted its wide range of assays, including the Atellica IM and ADVIA Centaur high-sensitivity troponin I assay which provide fast, accurate, actionable troponin I results to aid in the diagnosis of acute MI; the Atellica IM and ADVIA Centaur enhanced liver fibrosis test, a minimally invasive blood test with results that correlate to the level of liver fibrosis severity assessed by liver biopsy; the Atellica IM and ADVIA Centaur B·R·A·H·M·S Procalcitonin (PCT) assay which helps achieve earlier sepsis diagnosis and risk assessment to help improve patient outcomes with high low-end sensitivity; and the Atellica IM and ADVIA Centaur vitamin D total assay which helps evaluate the total amount of 25-hydroxy-vitamin D (both D2 and D3) in the blood to provide patients with accurate results, regardless of level and whether or not they are supplemented over-the-counter or by prescription.
Siemens also highlighted its range of point-of-care analyzers, including the epoc blood analysis system which offers complete blood gas and basic metabolic panel with hematocrit and lactate on a single room temperature-stable test card; the Xprecia Stride coagulation analyzer for PT/INR testing that provides high usability and lab-accurate results at the point-of-care; and the Atellica 1500 automated urinalysis system which combines fully automated urine sediment and chemistry analyzers into one streamlined system.
In the field of molecular diagnostics, Siemens demonstrated the Fast Track cycler for molecular testing that uses magnetic induction technology for robust and reliable results, and Syndromic real-time PCR multiplexing assays, one of the largest ranges of syndromically grouped real-time PCR multiplex assays covering the major infectious-disease groups.
Siemens also presented its digital healthcare solutions, including the Atellica Process Manager to operationalize processes with centralized oversight and advanced analytics; Atellica Data Manager to operationalize lab data with open, scalable test-, QC-, and result-management software; the Atellica Inventory Manager to analyze and automate inventory to reduce costs and save time; the POCcelerator Data Management System which is an open POC Informatics solution that can aggregate data from 180+ device models available from more than 40 different vendors; and the FastFinder Software, a fully automated real-time PCR interpretation platform that is compatible with select kits from Fast Track Diagnostics.
Latest MEDLAB 2019 News
- ERBA Group Launches New Hematology Analyzers at MEDLAB 2019
- Telstar Promotes Latest Generation of Freeze Dryers in Dubai
- Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer
- Mindray Displays New Generation Benchtop Cellular Analysis Line
- HORIBA Medical Shows Latest Yumizen G Range at Lab Trade Show
- Greiner Bio-One Displays Range of Safety Products at MedLab
- EKF Diagnostics Presents Latest Diabetes Care Analyzers
- BioSystems Highlights New iFOB Integral System at MedLab 2019
- Beckman Coulter Exhibits New Hematology Analyzer in Middle East
- Agappe Diagnostics Displays Analyzers and Solutions at Middle East Congress
- Abbott Highlights Point of Care Management Solutions
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








